Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 1997

View Archived Issues

Antibacterial agent isolated by Sanwa Kagaku

Green Cross claims hypolipidemic agents

Anthracyclines from Microbial Chemistry Research Foundation

Cell adhesion inhibitors disclosed by Nippon Shinyaku

New antibacterial agents from Daiichi

Bayer claims potassium channel modulators

Activated immunoglobulins reported by Nippon Zoki

AutoImmune reports 1996 fourth-quarter and year-end financial results

Chiroscience Group 1996/7 pharmaceutical development update

Genzyme Tissue Repair reports 1996 results

ICN reports record sales, net income and EPS for 1996 and fourth quarter

ViroPharma reports 1996 financial results

Salix completes filing for ulcerative colitis treatment

Nymox and MGH collaborate on gene therapy

John Wayne Cancer Institute initiates first clinical trials on Pseudomonas exotoxin

Array Medical's Actalyke system receives FDA approval

VIMRx and Columbia University create new gene research company

Pfizer initiates clinical trial in panic disorder

Genelabs Technologies and BMS reach agreement in Taiwan

Positive phase III results for GelTex's RenaGel

Genome Therapeutics and Versicor collaborate on new antibacterial compounds

Advanced-generation matrix HRT patch launched in U.K.

Pharmacyclic earns NCI support for anticancer compounds

Positive phase I results for new formulation of lexipafant

Zorac available in Germany

SKB's Vectavir introduced in Germany

German introduction for spirapril

Novo Nordisk and Dyax collaborate on drug discovery

First approval for naratriptan

GS-4104 enters human testing

U.S. patent for Sugen's lead cancer therapeutic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...